Identification of patients with COVID-19 who are optimal for methylprednisolone pulse therapy


Background: Corticosteroids have been reported to reduce the mortality rates in patients with coronavirus disease 2019 (COVID-19). Additionally, the role of high-dose methylprednisolone pulse therapy in reducing mortality in critically ill patients has also been documented. The purpose of this study is to identify patients with COVID-19 who are suitable for methylprednisolone pulse therapy.
Methods: This was a retrospective study that included patients with COVID-19 receiving methylprednisolone pulse therapy (>250 mg/day for 3 days) with subsequent tapering doses at our hospital between June 2020 and January 2021. We examined the differences in background clinical factors between the surviving group and the deceased group.
Results: Of 156 patients that received steroid therapy, 17 received methylprednisolone pulse therapy. Ten patients recovered (surviving group) and seven patients died (deceased group). The median age of the surviving and deceased groups was 64.5 years (range, 57-85) and 79 years (73-90), respectively, with a significant difference (p=0.004). Five of the deceased patients (71%) had developed serious complications associated with the cause of death, including pneumothorax, pneumomediastinum, COVID-19-associated pulmonary aspergillosis, cytomegalovirus infection, and bacteremia. On the other hand, of the 10 survivors, only one elderly person had cytomegalovirus infection and the rest recovered without complications.
Conclusion: Administration of methylprednisolone pulse therapy with subsequent tapering may be an effective treatment in patients with COVID-19 up to the age of early 70s; however, severe complications may be seen in elderly patients.



PlumX Metrics


Download data is not yet available.

Author Biography

Manabu Murakami, St. Luke’s International Hospital

Department of Pulmonary Medicine, Thoracic Center


The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021;384:693-704. DOI:

Sterne JA, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A meta-analysis. JAMA 2020;324:1330-41. DOI:

Edalatifard M, Akhtari M, Salehi M, Naderi Z, Jamshidi A, Mostafaei S, et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: Results from a randomised controlled clinical trial. Eur Respir J 2020;56:2002808. DOI:

So C, Ro S, Murakami M, Imai R, Jinta T. High-dose, short-term corticosteroids for ARDS caused by COVID-19: a case series. Respirol Case Reports 2020;8:e00596. DOI:

Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020;395:473-5. DOI:

Ko JJ, Wu C, Mehta N, Wald-Dickler N, Yang W, Qiao R. Methylprednisolone and dexamethasone in intensive care patients with COVID-19. J Intensive Care Med 2021;36:673-80. DOI:

Jeronimo CMP, Farias MEL, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, et al. Methylprednisolone as adjunctive therapy for patients hospitalized with Coronavirus Disease 2019 (COVID-19; metcovid): A randomized, double-blind, phase IIb, placebo-controlled trial. Clin Infect Dis 2021;72:e373-81.

Fernández-Cruz A, Ruiz-Antorán B, Muñoz-Gómez A, Sancho-López A, Mills-Sánchez P, Centeno-Soto GA, et al. A retrospective controlled cohort study of the impact of glucocorticoid treatment in SARS-CoV-2 infection mortality. Antimicrob Agents Chemother 2020;64:e01168-20. DOI:

Mareev VY, Orlova YA, Pavlikova EP, Matskeplishvili S, Krasnova TN, Malahov PS, et al. Steroid pulse-therapy in patients with coronAvirus Pneumonia (COVID-19), sYstemic inFlammation and Risk of vEnous thRombosis and thromboembolism (WAYFARER Study). Kardiologiya 2020;60:15-29. DOI:

Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020;584:430-6. DOI:

Martinelli AW, Ingle T, Newman J, Nadeem I, Jackson K, Lane ND, et al. COVID-19 and pneumothorax: A multicentre retrospective case series. Eur Respir J 2020;56:2002697. DOI:

Koehler P, Bassetti M, Chakrabarti A, Chen SC, Colombo AL, Hoenigl M, et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis 2021;21:e149-62. DOI:

Limaye AP, Kirby KA, Rubenfeld GD, Leisenring WM, Bulger EM, Neff MJ, et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA 2008;300:413-22. DOI:

Ko JH, Peck KR, Lee WJ, Lee JY, Cho SY, Ha YE, et al. Clinical presentation and risk factors for cytomegalovirus colitis in immunocompetent adult patients. Clin Infect Dis 2015;60:e20-6. DOI:

Short Reports
Coronavirus disease 2019, corticosteroids, pulse steroid therapy, methylprednisolone, complications
  • Abstract views: 1783

  • PDF: 231
  • HTML: 0
How to Cite
Ro, S., Nishimura, N., Imai, R., Tomishima, Y., So, C., Murakami, M., Okafuji, K., Kitamura, A., Jinta, T., & Tamura, T. (2021). Identification of patients with COVID-19 who are optimal for methylprednisolone pulse therapy. Multidisciplinary Respiratory Medicine, 16.